PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2013 December 1.
Published in final edited form as:
PMCID: PMC3580219
NIHMSID: NIHMS414644

Autoimmunity: Twenty Years in the Fas Lane

Just over twenty years ago, Shige Nagata and colleagues forged an important link between defective apoptosis and autoimmunity when they discovered that loss–offunction mutations in the gene encoding the TNF family cell surface receptor Fas/CD95 formed the genetic basis of the syndrome of lymphoproliferation and autoimmunity in the lpr mouse strain (1). Even before the linkage to Fas mutations, lpr mice had served as a model for human systemic lupus erythematosus (SLE). However, the discovery of mutations in Fas not only provided a molecular explanation for the lpr phenotype, but also inspired investigations that led to the discovery of Fas mutations in human familial autoimmune diseases and spurred research that discovered the molecular mechanisms underlying Fas-induced apoptosis. Recent findings have expanded the role of Fas beyond simply inducing apoptosis and prompted a re-examination of the original premise that autoimmunity in the context of Fas deficiency results simply from defective immune cell death.

Homozygous lpr/lpr mutant mice spontaneously produce a wide variety of autoantibodies to nuclear antigens with a striking resemblance to those found in the sera of patients with SLE (2). Massive lymphadenopathy and splenomegaly develop in these mice, hence the name lymphoproliferation (lpr). The primary cell type accumulating in the lymph nodes and spleen are αβTCR-expressing T cells lacking CD4 and CD8 (termed ‘double negative’ T cells, or DNT) and additionally expressing the CD45 isoform B220. These T cells are oligoclonal but not malignant, and besides being thymus dependent, their origins remain obscure. DNT are unlikely to be the cells that provide help for autoreactive B cells because they are anergic to TCR stimulation and poor producers of cytokines. Reducing the T cell repertoire with a TCR transgene eliminates production of DNT cells but not autoantibody production, showing that DNT cells are not required for autoimmunity in lpr mice (3). Conventional T cells, especially with a memory phenotype, and B cells also accumulate to greater than normal numbers in lpr mice. Background genes are important modifiers of the lpr phenotype, as renal disease and other organ manifestations such as arthritis, vasculitis, and salivary gland and skin inflammation primarily develop in lpr mice back-crossed onto the MRL genetic background (2, 4).

Once Nagata’s group had cloned the mouse Fas locus (5), the identification of Fas mutations in lpr mice using the genetic techniques available at that time was relatively straightforward. As described by Nagata in a 2004 interview, he usually tried to map the loci of genes cloned in the lab to see if there was any relevance to disease (6). Collaborators Nancy Jenkins and Neal Copeland at NIH mapped the mouse Fas locus to a location on chromosome 19, close to where the lpr locus had previously been mapped (7). Rather than proceeding to positional cloning and sequencing, which would likely have taken additional years of effort, the authors made the leap to directly test for Fas expression by northern blotting and immediately hit the genetic ‘jackpot,’ finding that cells from lpr/lpr mice expressed almost no detectable Fas mRNA. Although Watanabe-Fukunaga et al. found alterations in the Fas genomic locus in lpr mice by southern blotting, the exact nature of the genetic lesion was elucidated by Keith Elkon’s group, which showed that Fas transcription was disrupted in the lpr locus by a retrotransposon insertion (8). Watanabe-Fukunaga et al. did solve the mystery of another Fas allele, lprcg, which turned out to be a missense mutation in exon 9, which encodes the death domain. The Fas lprcg mutant protein was non-functional for apoptosis induction. The lprcg allele also had the interesting property of being able to complement the gld (generalized lymphadenopathy) locus with a similar phenotype. This suggested that the gld locus was functionally linked to Fas, and in 1994, Nagata’s group, which had recently cloned the Fas ligand (FasL) gene (9), and a team at Immunex and Duke University identified disabling point mutations in the extracellular domain of FasL as the cause of the gld syndrome (10, 11).

Although Watanabe-Fukunaga et al. speculated that Fas mutations identified in lpr syndrome may also cause human autoimmune conditions, no human diseases linked to either Fas mutations or defective Fas-mediated apoptosis had so far been described. Just at that time however, clinical investigators were evaluating patients who turned out to have an immune disorder remarkably similar to that seen in lpr mice. The findings linking the lpr phenotype to Fas mutations undoubtedly accelerated the discovery of Fas mutations responsible for human disease. At the National Institutes of Health’s Clinical Center in Maryland, virologist Steven Straus was referred a number of patients with chronic lymphadenopathy for evaluation of possible EBV infection as a factor in their disease. Characterization of these patients in collaboration with Mike Sneller, a fellow in Warren Strober’s group at NIH, revealed a significant pattern of autoimmunity, primarily autoantibody-mediated hemolytic anemia, thrombocytopenia, and splenomegaly and lymphadenopathy with underlying polyclonal expansion of B cells and αβTCR-positive T cells lacking CD4 and CD8 (12). In this paper, the authors presciently speculated about the similarities between these patients and lpr and gld mice.

The discovery linking Fas to the lpr mouse phenotype led to discussions at NIH about the possibility of Fas mutations and apoptosis defects in this syndrome with immunologist Mike Lenardo, a discoverer of the phenomenon of TCR-induced apoptosis, who demonstrated an apoptosis defect in the patient cells. The team was joined by geneticist and clinical immunologist Jennifer Puck, who showed that missense mutations in Fas coding sequences clustering in the death domain were inherited in an autosomal dominant fashion in five independent families with this disorder, which was named the Autoimmune Lymphoproliferative Syndrome, or ALPS (13). Expression of the mutant protein blocked Fas-induced apoptosis in normal cells, and T cells from ALPS patients also failed to undergo death due to restimulation through the TCR (Restimulation-Induced Cell Death, or RICD) (13). These data confirmed findings about the role of Fas in RICD in CD4+ T cells made around the same time (1416). Independently, Frederic Rieux-Laucat and colleagues in Paris (17) and Keith Elkon’s group in New York (18) identified Fas mutations in similar groups of patients, some of whom had been described in the 1960’s as having Canale-Smith syndrome, with many of the same clinical features as what became known as ALPS. Cohorts of patients with ALPS were subsequently described around the world (1921). Today, there are likely to be at least 500 families, about 80% of whom have Fas mutations, with the clinical syndrome of ALPS fitting recently revised diagnostic criteria (22). While most Fas mutations in ALPS are inherited, some patients with a similar clinical syndrome but without germline Fas mutations were found to have somatic point mutations in Fas that likely underlie their disease (23). Mutations found in other non-Fas-related genes in ALPS patients have further shed light on apoptosis signaling pathways (22). Ironically, despite lpr mice serving as a model for systemic lupus in humans, investigation of mutations or polymorphisms in Fas in patients with SLE and unbiased whole genome association studies of SLE susceptibility loci have not yielded evidence of common or rare genetic variants in Fas that drive susceptibility to lupus. Although its usefulness as a single-gene model of autoimmunity was not diminished, these findings made it clear that lpr is a mouse model for ALPS, rather than lupus.

The discoveries that Fas mutations can cause genetic autoimmune disease in both mouse and man triggered intensive study of this receptor and the molecular basis of transmembrane signaling initiated by Fas. Within the next four years, the essential components of the “Death-inducing Signaling Complex” (DISC) that are recruited to the Fas death domain (24) were elucidated. The adaptor protein FADD and the cysteinyl aspartic protease, caspase-8, were found to be essential components required for Fas-induced apoptosis (2527). Aggregation in the Fas DISC activates caspase-8, which in turn catalyzes the cleavage of downstream or “effector” caspase-3, activation of which results in irreversible cell death. In some cells, amplification of the cell death signal through the mitochondria is also required (28). Fas and FasL can form homotrimers, but a number of lines of evidence suggest that formation of receptor oligomers beyond the 3:3 complex of Fas with FasL is critical for effective activation of Fas apoptotic signaling. Only membrane-bound FasL is capable of triggering active downstream receptor complexes and soluble FasL cannot induce Fas-induced apoptosis in vitro or in vivo (29, 30). The crystal structure of Fas and FADD consists of five receptor oligomers, suggesting at least a dimer of Fas trimers as the minimal active signaling complex (31), and microscopically visible clusters of receptors are seen after receptor ligation (32, 33). Fas clustering and efficient signaling is supported by receptor localization in lipid rafts, which is mediated by palmitoylation of a membrane-proximal cysteine (3436), and pre-association of receptor chains is mediated by a separate domain from ligand binding (37).

Despite their essential role in Fas apoptotic signaling, analysis of the in vivo role of FADD and caspase-8 has revealed additional unexpected functions. FADD- and caspase-8-deficient mice were found to be embryonically lethal and revealed that these molecules were also required for efficient hematopoietic and T cell development (3840). Patients homozygous for a hypomorphic mutation in caspase-8 had reduced Fas-induced apoptosis in their T cells, but also significant immunodeficiency and T cell activation defects distinct from those of Fas-deficient ALPS patients (41). A role for FADD and caspase-8 in preventing programmed necrosis has recently provided an explanation for these apparently paradoxical functions (4245), as FADD- or caspase-8- deficient cells may default into programmed necrosis and become eliminated more easily when Fas or other activating stimuli are given.

Apart from preventing programmed necrosis, Fas can deliver signals that oppose cell death in a number of contexts (46). Fas can costimulate T cell activation (47, 48), and non-apoptotic Fas signaling contributes to liver regeneration in partial hepatectomy models (49, 50). Fas is expressed on most primary T cells after activation, but only a small fraction of T cells, primarily those with an effector memory phenotype, are highly susceptible to Fas-induced apoptosis (51, 52). It has become clear that the intrinsic cell death machinery, regulated primarily by the bcl-2 family of proteins, particularly the pro-apoptotic BH3 domain-containing protein bim, controls apoptosis independently of Fas during thymic negative selection and the clonal contraction of T cells after acute antigenic stimulation (53, 54). Fas-FasL interactions are only required for the elimination of T cells responding to repeatedly administered antigens such as occurs during chronic infections (14, 55, 56). The non-apoptotic pathway may be the dominant function in Fas-expressing tumor cells where Fas is highly expressed, and loss of Fas in hepatic and ovarian tumors can result in tumor regression in mouse models (57). These findings brought the understanding of Fas and apoptosis signaling full circle from its initial discovery as a receptor for Abs that induce apoptosis in tumor cells (58).

Even with all these advances over the past two decades, a number of fundamental questions about how Fas prevents autoimmunity still remain to be addressed. Although the apoptotic defect in Fas-deficient cells is easy to demonstrate in vitro in activated T cells, it is not clear that this defect is responsible for the loss of self-tolerance that results in autoimmunity in Fas deficiency. Experiments with mice lacking Fas expression specifically in T cells, B cells, or dendritic cells revealed that autoimmunity can result from deletion of Fas in any of these compartments (59, 60), though deletion of Fas in any single cell lineage could not reproduce the syndrome of complete Fas deficiency. Less is known about how Fas signaling is regulated in B cells and other cell types. In another of their many contributions to the understanding of the biology of Fas/CD95, Nagata’s group discovered that anti-Fas Abs cause lethal hepatic necrosis due to engagement of Fas on hepatocytes, limiting the therapeutic use of anti-Fas Abs to eliminate autoreactive immune cells (61). Thus, understanding how cells control whether they die, survive, or proliferate after Fas engagement, and what other signals influence this cell fate decision, remains important for the design of immunotherapies that target this remarkable receptor (62).

Acknowledgments

We would like to thank Mike Lenardo and Mike Sneller for discussions about the history of the discovery of ALPS and Fas mutations in humans, and Vera Siegel for proofreading the manuscript.

References

1. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–317. [PubMed]
2. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol. 1991;9:243–269. [PubMed]
3. Mountz JD, Zhou T, Eldridge J, Berry K, Bluthmann H. Transgenic rearranged T cell receptor gene inhibits lymphadenopathy and accumulation of CD4–CD8-B220+ T cells in lpr/lpr mice. J Exp Med. 1990;172:1805–1817. [PMC free article] [PubMed]
4. Kelley VE, Roths JB. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol. 1985;37:220–229. [PubMed]
5. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. Journal of Immunology. 1992;148:1274–1279. [PubMed]
6. Nagata S. Early work on the function of CD95, an interview with Shige Nagata. Cell Death Differ. 2004;11(Suppl 1):S23–27. [PubMed]
7. Watanabe T, Sakai Y, Miyawaki S, Shimizu A, Koiwai O, Ohno K. A molecular genetic linkage map of mouse chromosome 19, including the lpr, Ly-44, and Tdt genes. Biochemical genetics. 1991;29:325–335. [PubMed]
8. Chu JL, Drappa J, Parnassa A, Elkon KB. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med. 1993;178:723–730. [PMC free article] [PubMed]
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor … Cell 1993 [PubMed]
10. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davissmith T, Smith CA, Hunter K, Bhat D, Din W, Goodwin RG, Seldin MF. The Mouse Fas-Ligand Gene Is Mutated in Gld Mice and Is Part of a Tnf Family Gene-Cluster. Immunity. 1994;1:131–136. [PubMed]
11. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969–976. [PubMed]
12. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, Strober W. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest. 1992;90:334–341. [PMC free article] [PubMed]
13. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–946. [PubMed]
14. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444–448. [PubMed]
15. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature. 1995;373:438–441. [PubMed]
16. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation- induced apoptosis in T-cell hybridomas. Nature. 1995;373:441–444. [PubMed]
17. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–1349. [PubMed]
18. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643–1649. [PubMed]
19. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM, Lenardo MJ, Straus SE. Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341–1348. [PubMed]
20. Infante A, Britton H, DiNapoli T, MLA, Lenardo M, Jackson C, Wang J, Fleisher T, Straus S, Puck J. The Clinical Spectrum in a large kindred with ALPS due to a Fas mutation that impairs lymphocyte apoptosis. J Pediatrics. 1998 In Press. [PubMed]
21. Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, La Grutta S, Correra A, Notarangelo LD. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89:902–909. [PubMed]
22. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT, Rao VK. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35–40. [PubMed]
23. Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, Blanche S, Bartunkova J, Vilmer E, Fischer A, Le Deist F, Rieux-Laucat F. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351:1409–1418. [PubMed]
24. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO Journal. 1995;14:5579–5588. [PubMed]
25. Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505–512. [PubMed]
26. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1995;85:803–815. [PubMed]
27. Muzio M, Chinnaiyan AM, Kischkel FC, O’Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell. 1996;85:817–827. [PubMed]
28. Scaffidi C, Scaffidi C, Fulda S, Fulda S, Srinivasan A, Srinivasan A, Friesen C, Friesen C, Li F, Li F, Tomaselli KJ, Tomaselli KJ, Debatin KM, Debatin KM, Krammer PH, Krammer PH, Peter ME, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675. [PubMed]
29. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428–1440. [PMC free article] [PubMed]
30. O’ Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 2009;461:659–663. [PMC free article] [PubMed]
31. Wang L, Yang JK, Kabaleeswaran V, Rice AJ, Cruz AC, Park AY, Yin Q, Damko E, Jang SB, Raunser S, Robinson CV, Siegel RM, Walz T, Wu H. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol. 2010;17:1324–1329. [PMC free article] [PubMed]
32. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, Straus SE, Lenardo MJ. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol. 2004;167:735–744. [PMC free article] [PubMed]
33. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 2002;22:207–220. [PMC free article] [PubMed]
34. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol. 2004;5:182–189. [PubMed]
35. Feig C, Tchikov V, Schütze S, Peter ME. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007;26:221–231. [PubMed]
36. Chakrabandhu K, Hérincs Z, Huault S, Dost B, Peng L, Conchonaud F, Marguet D, He HT, Hueber AO. Palmitoylation is required for efficient Fas cell death signaling. EMBO J. 2007;26:209–220. [PubMed]
37. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288:2354–2357. [PubMed]
38. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998;9:267–276. [PubMed]
39. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296–300. [PubMed]
40. Kabra NH, Kang C, Hsing LC, Zhang J, Winoto A. T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc Natl Acad Sci U S A. 2001;98:6307–6312. [PubMed]
41. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395–399. [PubMed]
42. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471:373–376. [PMC free article] [PubMed]
43. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, Caspary T, Mocarski ES. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471:368–372. [PMC free article] [PubMed]
44. Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol. 2011;12:757–763. [PMC free article] [PubMed]
45. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363–367. [PMC free article] [PubMed]
46. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zornig M, Lynch DH. The CD95 receptor: apoptosis revisited. Cell. 2007;129:447–450. [PubMed]
47. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993;178:2231–2235. [PMC free article] [PubMed]
48. Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med. 1999;190:1891–1896. [PMC free article] [PubMed]
49. Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O, Hacker G, Dittrich-Breiholz O, Kracht M, Scheurich P, Wajant H. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol. 2004;166:369–380. [PMC free article] [PubMed]
50. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med. 2000;6:920–923. [PubMed]
51. Riou C, Yassine-Diab B, Van grevenynghe J, Somogyi R, Greller LD, Gagnon D, Gimmig S, Wilkinson P, Shi Y, Cameron MJ, Campos-Gonzalez R, Balderas RS, Kelvin D, Sekaly RP, Haddad EK. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med. 2007;204:79–91. [PMC free article] [PubMed]
52. Ramaswamy M, Cruz AC, Cleland SY, Deng M, Price S, Rao VK, Siegel RM. Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains. Cell Death & Differentiation. 2011;18:712–720. [PMC free article] [PubMed]
53. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, Pellegrini M, Cory S, Adams JM, Strasser A. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415:922–926. [PubMed]
54. Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity. 2002;16:759–767. [PubMed]
55. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008;28:197–205. [PMC free article] [PubMed]
56. Hutcheson J, Scatizzi JC, Siddiqui AM, Haines GK, 3rd, Wu T, Li QZ, Davis LS, Mohan C, Perlman H. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity. 2008;28:206–217. [PubMed]
57. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 2010;465:492–496. [PMC free article] [PubMed]
58. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245:301–305. [PubMed]
59. Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton RA, Hartig H, Sundberg JP, Servick S, Kaufmann G, Fink PJ, Chervonsky AV. Elimination of antigen-presenting cells and autoreactive T cells by fas contributes to prevention of autoimmunity. Immunity. 2007;26:629–641. [PMC free article] [PubMed]
60. Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J, Chen NJ, Elia A, Wakeham A, Li WY, Liepa J, Wood GA, Casola S, Rajewsky K, Mak TW. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity. 2008;29:615–627. [PMC free article] [PubMed]
61. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–809. [PubMed]
62. Ramaswamy M, Deng M, Siegel RM. Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases. Nat Rev Rheumatol. 2011;7:152–160. [PMC free article] [PubMed]